Navigation Links
Acclarent, Inc. Closes $26 Million Financing
Date:1/11/2009

MENLO PARK, Calif., Jan. 12 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat, announced today the closing of a $26 million dollar financing round. Acclarent intends to use the proceeds to continue commercialization of its Balloon Sinuplasty(TM) Technology, as well as on-going investment in product development and clinical studies.

Johnson & Johnson Development Corporation (JJDC) joined existing prominent investors New Enterprise Associates, Inc., Delphi Ventures, Versant Ventures, and Meritech Capital Partners in this financing.

"The addition of JJDC together with the support of our existing financial partners will enable Acclarent to continue executing on our strategy to build the preeminent ENT Company," said Bill Facteau, Acclarent President and CEO.

About Johnson & Johnson Development Corporation. Organized in 1973, Johnson & Johnson Development Corporation is the venture capital subsidiary of Johnson & Johnson. JJDC makes private equity investments in venture funded health care companies. Portfolio companies include those in the fields of pharmaceuticals, biotechnology, medical devices, diagnostics and consumer products. JJDC also leads and manages internal investments in selected promising technologies. For more information, go to http://www.jjdevcorp.com.

About Acclarent, Inc.

Acclarent is a medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat. The company is currently focused on commercializing its Balloon Sinuplasty(TM) Devices, which are flexible, minimally-invasive tools that aid physicians in treating patients suffering from chronic sinusitis.


'/>"/>
SOURCE Acclarent, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. CellCyte Genetics Corporation: Seattle Times Erroneously Reports That CellCyte Closes
2. Pioneer(R) Surgical Technology, Inc. Closes $15 Million Series B Financing
3. Rcadia Medical Imaging Closes $3.3 Million Investment Led by BioVentures Investors
4. Oaks Development Group Closes on Third San Antonio Project
5. Cardiome Discloses Chairman And CEOs Involuntary Share Sale
6. Morgenthaler Closes Ninth Fund at $400 Million
7. Intelect Medical Closes $11 Million in Funding from Boston Scientific and Greatbatch for Stroke and TBI Recovery Clinical Trials
8. Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant
9. Response Biomedical Closes $5.1 Million Financing
10. Blue Cross Blue Shield of Michigan Closes Detroit Operations October 31 Due to Bomb Threat
11. Oaks Development Group Closes on 2.1 Acres for Medical Office Building in Palm Coast, FL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 06, 2016 , ... The Behavioral Health Center of Excellence ... organization as a top behavioral service provider in the country. The award celebrates ... satisfaction and qualifications, and consumer satisfaction. These areas are measured via a wide-ranging ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation involving human stem ... largely due to its potential for revolutionizing human disease treatment. There are multiple ... pluripotent stem cells (hiPSCs). , Both platforms have distinct advantages and disadvantages, ...
(Date:12/6/2016)... ... 06, 2016 , ... METTLER TOLEDO has launched its online ... white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, user ... documents, webinars and videos available online, visit the METTLER TOLEDO Expertise Library ...
(Date:12/6/2016)... ... ... 'Tis the season for family, festivity, food and fun! Temptation abounds, and ... eating healthy, staying active, and taking medication and doing daily foot health checks (a ... "Shopping trips, parties and family gatherings can take their toll on our feet during ...
(Date:12/6/2016)... B.C., Canada (PRWEB) , ... December 06, 2016 ... ... (STC) announce the availability of the newly updated International Audit Protocol Consortium (IAPC) ... use IAPC EHS audit protocols to understand the scope of their EHS regulatory ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Nov. 29, 2016 Several leading Alzheimer,s ... Accera, Inc. at 11 a.m. EST on ... Conference on Clinical Trials for Alzheimer,s Disease (CTAD). The ... in Alzheimer,s disease and therapeutic targets that address deficient ... "Following the recent failure of another therapy targeting the ...
(Date:12/5/2016)... , Dec 5, 2016 Research ... Market by Product (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease ... - Global Forecasts to 2021" report to their offering. ... , , ... USD 730.7 Million in 2021 from USD 574.8 Million in 2016, ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Product Type and by Application - Global Opportunity Analysis and Industry ... in 2015, and is expected to reach $5,255 million by 2022, growing at ... market in 2015 with more than four-fifths share. ... ...
Breaking Medicine Technology: